Politics & Pharmaceutical Industry

0
282

This post may contain affiliate links. We may earn money or products from the highlighted keywords or companies mentioned in this post.

Clinton has the odds in favor of her – which is a good thing for the global equity says hedge fund manager Jamie Dinan in an interview with CNBC. However, not all businesses are happy about it. Health-care stocks have been declining as Clinton widens the lead gap.

So far, the S&P 500 index posting showed that while other groups were posting positive trends, the health-care industry seems to be deviating from the optimistic climate – this is the only group that has been consistently posting losses in year 2016. Reports show that six health-care companies recorded that biggest stock declines this year. Just last week, the general overview on the group saw a decline of 3.3% – this has been their biggest recorded loss in a span of five days since February. Their performance has been dismal where this has been down by 2.6% in 2016. Investors are now gauging if the industry will still have potential to grow once Clinton becomes the president of the United States.

Pharmaceutical companies have more problems in their hands aside from the presidential candidate. Other politicians have expressed their disdain on the increasing prices of old drugs. Senator Bernie Sanders criticized Ariad Pharmaceuticals Inc. as being greedy in his tweet after the company issued a price increase for a certain cancer drug. The simple tweet was powerful enough to pull down their share price by as much as 15%. Dan Clifton of the Strategas Research Partners in Washington says that the Pharma and biotech industries have the most at stake this election compared to other groups.

In the past, pharmaceutical companies have been reported to have worked with the government agencies to kill their competition such as those that offered natural-based products and people who practiced alternative medicine. They have also been accused of killing projects such as the cancer treatment that was discovered by Dr. Rife (which never made it to the market). If Clinton wins the presidential elections, then their monopoly on the health industry could be well over, which is bad for their business, but also good for the patients who are in need of real treatment.

Outside of the pharmaceutical markets, the e-cigarette or vape market is now gaining a tremendous amount of momentum as well. Companies  are offering great alternatives for smokers looking to quit or cut back while improving their quality of health at the same time.